Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits

Ellen M.H. Schmitz, Daan van de Kerkhof, Dörte Hamann 5 , Joost L.J. van Dongen, Philip H.M. Kuijper, Luc Brunsveld, Volkher Scharnhorst, and Maarten A.C. Broeren
  • 1 Expert Center Clinical Chemistry Eindhoven, Eindhoven, The Netherlands
  • 2 Máxima Medical Center Veldhoven, Clinical Laboratory, Veldhoven, The Netherlands
  • 3 Catharina Hospital Eindhoven, Clinical Laboratory, Eindhoven, The Netherlands
  • 4 Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands
  • 5 Laboratory for Monoclonal Therapeutics, Sanquin Diagnostics, Amsterdam, The Netherlands
  • 6 Klinisch chemisch laboratorium, Máxima Medisch Centrum Veldhoven, Postbus 7777, 5500 MB Veldhoven, The Netherlands
Ellen M.H. Schmitz, Daan van de Kerkhof, Dörte Hamann, Joost L.J. van Dongen, Philip H.M. Kuijper, Luc Brunsveld, Volkher Scharnhorst and Maarten A.C. Broeren

Abstract

Background: Therapeutic drug monitoring (TDM) of infliximab (IFX, Remicade®) can aid to optimize therapy efficacy. Many assays are available for this purpose. However, a reference standard is lacking. Therefore, we evaluated the analytical performance, agreement and clinically relevant differences of three commercially available IFX ELISA kits on an automated processing system.

Methods: The kits of Theradiag (Lisa Tracker Infliximab), Progenika (Promonitor IFX) and apDia (Infliximab ELISA) were implemented on an automated processing system. Imprecision was determined by triplicate measurements of patient samples on five days. Agreement was evaluated by analysis of 30 patient samples and four spiked samples by the selected ELISA kits and the in-house IFX ELISA of Sanquin Diagnostics (Amsterdam, The Netherlands). Therapeutic consequences were evaluated by dividing patients into four treatment groups using cut-off levels of 1, 3 and 7 μg/mL and determining assay concordance.

Results: Within-run and between-run imprecision were acceptable (≤12% and ≤17%, respectively) within the quantification range of the selected ELISA kits. The apDia assay had the best precision and agreement to target values. Statistically significant differences were found between all assays except between Sanquin Diagnostics and the Lisa Tracker assay. The Promonitor assay measured the lowest IFX concentrations, the apDia assay the highest. When patients were classified in four treatment categories, 70% concordance was achieved.

Conclusions: Although all assays are suitable for TDM, significant differences were observed in both imprecision and agreement. Therapeutic consequences were acceptable when patients were divided in treatment categories, but this could be improved by assay standardization.

    • Supplementary material
  • 1.

    Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel J, Allez M, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6:991–1030.

    • Crossref
    • PubMed
    • Export Citation
  • 2.

    Schnitzler F, Fidder H, Ferrrante M, Noman M, Arijs I, Assche van G, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut 2009;58:492–500.

    • Crossref
    • PubMed
    • Export Citation
  • 3.

    Rinaudo-Gaujous M, Roblin X, Marotte H, Paul S. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis 2015;74:e40.

    • Crossref
    • PubMed
    • Export Citation
  • 4.

    van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, et al. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis 2015;74:311–4.

    • Crossref
    • PubMed
    • Export Citation
  • 5.

    Baert F, Noman M, Vermeire S, van Assche G, D’Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003;348:601–8.

    • Crossref
    • PubMed
    • Export Citation
  • 6.

    Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn’s disease. Am J Gastroenterol 2008;103:944–8.

    • Crossref
    • PubMed
    • Export Citation
  • 7.

    Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol 2006;4:1248–54.

    • Crossref
    • PubMed
    • Export Citation
  • 8.

    Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010;59:49–54.

    • Crossref
    • PubMed
    • Export Citation
  • 9.

    Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711–5.

    • Crossref
    • PubMed
    • Export Citation
  • 10.

    Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatol 2007;46:1828–34.

    • Crossref
    • Export Citation
  • 11.

    Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J, Christensen LA, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2014;63:919–27.

    • Crossref
    • PubMed
    • Export Citation
  • 12.

    van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut 2014;63:72–9.

    • Crossref
    • PubMed
    • Export Citation
  • 13.

    Vande Casteele NV, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn’s disease. Gut 2014;64:1539–45.

    • PubMed
    • Export Citation
  • 14.

    Adedokun OJ, Sandborn WJ, Feagan BG, Rutgeers P, Xu Z, Marano CW, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology 2014;147:1296–307.

    • Crossref
    • PubMed
    • Export Citation
  • 15.

    Reinisch W, Feagan BG, Rutgeerts PJ, Adedokun OJ, Cornilie FJ, Diamond R, et al. Infliximab concentration and clinical outcome in patients with ulcerative colitis. Gastroenterology 2012;142:S-114.

  • 16.

    Vande Casteele NV, Compernolle G, Ballet V, van Assche G, Gils A, Vermeire S, et al. Results on the optimisation phase of the prospective controlled trough level adapted infliximab treatment (TAXIT) Trial. Gastroenterology 2012;142:S-211–12.

    • Crossref
    • Export Citation
  • 17.

    Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, van Steen K, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015;148:1320–9.

    • Crossref
    • PubMed
    • Export Citation
  • 18.

    van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GH, et al. Response to: the antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis 2015;74:e41.

    • Crossref
    • PubMed
    • Export Citation
  • 19.

    Chaudhary MA, Fan T. cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis in the Netherlands. Biol Ther 2013;3:45–60.

    • Crossref
    • PubMed
    • Export Citation
  • 20.

    Velayos FS, Kahn JG, Sandborn WJ, Feagan BG. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn’s disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol 2013;11:654–66.

    • Crossref
    • PubMed
    • Export Citation
  • 21.

    Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:704–7.

    • Crossref
    • PubMed
    • Export Citation
  • 22.

    Ternant D, Mulleman D, Degenne D, Willot S, Guillaumin J, Watier H, et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit 2006;28:169–74.

    • Crossref
    • PubMed
    • Export Citation
  • 23.

    Vande Casteele N, Buurman DJ, Sturkenboom MG, Kleibeuker JH, Vermeire S, Rispens T, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012;36:765–71.

    • Crossref
    • PubMed
    • Export Citation
  • 24.

    Wang S, Ohrmund L, Hauenstein S, Salbato J, Reddy R, Monk P, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods 2012;382:177–88.

    • Crossref
    • PubMed
    • Export Citation
  • 25.

    Ruiz-Argüello B, del Agua AR, Torres N, Monasterio A, Martínez A, Nagore D. Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med 2013;51:e287–9.

    • PubMed
    • Export Citation
  • 26.

    Steenholdt C, Ainsworth MA, Tovey M, KLausen TW, Thomsen OØ, Brynskov J, et al. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn’s disease. Ther Drug Monit 2013;35:530–8.

    • Crossref
    • PubMed
    • Export Citation
  • 27.

    Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn’s disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol 2014;109:1055 64.

    • PubMed
    • Export Citation
  • 28.

    Rispens T, van der Klei D. Reply to: comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med 2013;51:e291–2.

    • PubMed
    • Export Citation
  • 29.

    Van Stappen T, Brouwers E, Tops S, Geukens N, Vermeire S, Declerck PJ, et al. Generation of a highly specific monoclonal anti-infliximab antibody for harmonization of TNF-coated infliximab assays. Ther Drug Monit 2015;37:479–85.

    • Crossref
    • PubMed
    • Export Citation
  • 30.

    apDia. Package insert In vitro diagnostic kit Infilximab ELISA 2014.

  • 31.

    Progenika Biopharma. Package insert Promonitor-IFX; 2012.

  • 32.

    Theradiag. Package insert LISA-TRACKER Duo Infliximab; 2014.

  • 33.

    Clinical and Laboratory Standards Institute (CLSI). User verification of performance for precision and trueness; approved guideline, 2nd Ed. CLSI document EP15-A2. Pennsylvania: Clinical and Laboratory Standards Institute, 2005:19087-1898.

  • 34.

    Chesher D. Evaluating assay precision. Clin Biochem Rev 2008;29:S23.

    • PubMed
    • Export Citation
  • 35.

    Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem 1983;21:709–20.

    • PubMed
    • Export Citation
  • 36.

    Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307–10.

    • PubMed
    • Export Citation
  • 37.

    Vande Casteele NV, Feagan BG, Gils A, Vermeire S, Khanna R, Sandborn WJ, et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep 2014;16:1–8.

  • 38.

    Gils A, Storme R, Dreesen E, Van Stappen T, Declerck PJ. The biosimilars of infliximab are equally well quantified in a clinically validated infliximab assay. J Crohns Colitis 2015;9:S97–S97.

    • Crossref
    • Export Citation
Purchase article
Get instant unlimited access to the article.
$42.00
Log in
Already have access? Please log in.


or
Log in with your institution

Journal + Issues

Search